DarioHealth Earnings Call Transcripts
Fiscal Year 2025
-
Record new business wins in 2025 offset a legacy client loss, with Q4 revenue growth and expanding gross margins. Pipeline value surged to $122 million, and cost discipline plus AI efficiencies are expected to drive a 30% reduction in operating loss in 2026, targeting cash flow breakeven by mid-2027.
-
Q3 2025 revenue declined to $5 million due to a strategic shift to high-margin recurring revenue, but gross margins and operating efficiency improved significantly. With 45 new accounts signed YTD and a robust pipeline, the company targets $12.4 million in new business for 2026 and expects to reach cash flow breakeven by late 2026 to early 2027.
-
Q2 2025 revenue declined due to a large health plan non-renewal and slower new client ramp-up, but gross margins improved and operating expenses fell sharply. The pipeline and ARR commitments are strong, with AI-driven efficiencies and new partnerships expected to drive growth into 2026.
-
Q1 2025 revenue grew 17% year-over-year to $6.75M, with strong B2B2C margins and 14 new clients. Operational efficiencies, AI integration, and major account launches are expected to drive break-even by year-end, despite some revenue delays from account transitions and tariffs.
Fiscal Year 2024
-
2024 saw strong revenue growth, margin expansion, and a shift to a unified AI-powered digital health platform. The company targets 50% client growth in 2025, with GLP-1 solutions and multi-condition care as key drivers, and expects to reach operational break-even by year-end.
-
Q3 2024 saw 111% year-over-year revenue growth, margin expansion, and a shift to recurring revenue, driven by new client wins and the integration of Twill. Cost reductions and a strong pipeline support a $50M run rate and cash flow break-even by end of 2025.
-
B2B2C revenue grew 60% sequentially and 315% year-over-year, now driving 75% of total revenue with 82% gross margin. Strategic cost reductions and a shift to recurring pharma revenue support the goal of profitability by end of 2025.